Key result
Mitral annuloplasty shows no survival or MACCE difference versus replacement but is linked to larger LVEDD.
Why the study?
Does mitral valve annuloplasty compared to mitral valve replacement improve survival or reduce MACCE in patients with severe chronic ischemic mitral regurgitation?
Population
436 consecutive patients with severe chronic ischemic mitral regurgitation (CIMR)
Comparison
Mitral valve annuloplasty (MVA) vs Mitral valve replacement (MVR)
Design
Cohort
Follow-up
59 months (interquartile range, 37-85 months)
Authors
Loading...
Annuloplasty was associated with similar survival/MACCE but larger LVEDD versus replacement; leaves open optimal surgical strategy for ischemic MR.
Cohort (n=436)
Does mitral valve annuloplasty compared to mitral valve replacement improve survival or reduce MACCE in patients with severe chronic ischemic mitral regurgitation?
Mitral valve replacement is a suitable alternative to annuloplasty for severe ischemic mitral regurgitation, offering better ventricular remodeling and lower MACCE risk in younger patients with reduced ejection fraction.
Li et al. (2018) conducted a cohort in Severe chronic ischemic mitral regurgitation (CIMR) (n=436). Mitral valve annuloplasty (MVA) vs. Mitral valve replacement (MVR) was evaluated on Overall survival, freedom from cardiac death, or avoidance of major adverse cardiac or cerebrovascular events (MACCE). Mitral valve annuloplasty compared to replacement showed no significant difference in overall survival or MACCE, but resulted in a larger left ventricle end-diastolic diameter (P=0.019).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: